Stocks · News reference

Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk

Jul 29, 2026, 4:03 PMAkanksha Bakshi

Entera Bio financing lifts ENTX as investors weigh a $275 million cash boost, EB613 funding and dilution risk.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 4, 2026, 12:03 PMAvi Kapoor
Oxford Industries Posts Mixed Q2 Results, Joins Asana, Lululemon Athletica And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures mixed; Oxford Industries fell 12.6% after mixed results. Lululemon, Guidewire, Asana and UiPath also dropped premarket.
ASAN AXG CD ENTX GWRE
BenzingaAug 21, 2026, 8:21 PMBenzinga News-desk
Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm
ENTX
SEC EDGARAug 18, 2026, 12:00 PMSEC EDGAR
8-K filing — Entera Bio Ltd. (ENTX)
Filed: 2026-08-18 AccNo: 0001178913-26-004178 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
ENTX
BenzingaAug 7, 2026, 8:25 PMBenzinga Newsdesk
Entera Bio Q2 EPS $(0.14) Misses $(0.08) Estimate
ENTX